What Biosyn does

Biosyn Corporation is a privately held biopharmaceutical company founded in 1984 in Germany and incorporated in the United States in 1994/1995, headquartered in Carlsbad, California. The company specializes in the manufacture of Keyhole Limpet Hemocyanin (KLH) and Immunocyanin products derived from the hemolymph of the Giant Keyhole Limpet (Megathura crenulata) using proprietary non-lethal extraction, mariculture/aquaculture, GMP-grade purification, and lyophilization processes. Its core product portfolio spans IMMUCOTHEL® (the first hemocyanin product approved for bladder cancer immunotherapy, marketed in the Netherlands, Austria, Argentina, and South Korea), VACMUNE® (a KLH carrier protein for vaccine manufacture and immunology research), Native KLH (multiple research and GMP grades), the newer Reassociated Native KLH (RANKLH) launched in 2023 for conjugate vaccine manufacturers, and Selenase® (sodium selenite pentahydrate), a selenium drug product registered in 18+ countries and under FDA Drug Master File in the United States.

The company operates a fully validated GMP facility in Carlsbad, CA (completed 2001) including specialized aquaria for non-lethal handling of Giant Keyhole Limpets, and a wholly-owned German manufacturing subsidiary, biosyn Arzneimittel GmbH in Fellbach, where final GMP KLH products are finished. Revenue is generated through direct, sales-led enterprise engagement with pharmaceutical and academic research customers — including 3 of the 10 largest global pharmaceutical companies — via quote-based, multi-year contracts for bulk and vialed hemocyanin and selenium products in research and clinical/GMP grades. Pricing is not publicly disclosed. The company also provides regulatory and scientific support to customers using its products in investigational and commercial applications across multiple jurisdictions. Leadership rests with Dr. S.N. Muddukrishna as President and CEO; Mark O'Reilly is identified as a Managing Partner. No public ticker, funding rounds, or cap-table information is disclosed.

Name

Biosyn

Legal name

biosyn Corporation

Website

https://biosyncorp.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

11–50 employees

Short description

Biosyn Corporation is a privately held biopharmaceutical company that manufactures clinical/GMP and research-grade Keyhole Limpet Hemocyanin (KLH) products and the selenium drug Selenase® for bladder cancer immunotherapy, vaccine manufacture, and selenium deficiency treatment across 18+ countries.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm) (HLAMAEAD)

Keywords

• Hemocyanin manufacturing
• Immunotherapy products
• Vaccine carrier proteins
• Selenium pharmaceuticals
• Biopharmaceutical products

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Sales of hemocyanin/immunocyanin products: Sales of KLH products (IMMUCOTHEL®, VACMUNE®, Native KLH, Reassociated KLH) in research grade and clinical/GMP grade formats, available as bulk and vialed products for investigational study use or non-clinical uses requiring GMP grade material.
2. Licensed drug product sales (Selenase®): Sales of selenase® (sodium selenite pentahydrate), registered as a drug product in more than 18 countries (Europe, Russia, Asia, South America) for selenium deficiency. In the U.S., marketed as an investigational product only.
3. Regulatory and scientific support services: Provision of scientific and regulatory support to customers using biosyn hemocyanin products for research and development, supporting investigational and commercial purposes across global jurisdictions.

Pricing tiers

Go-to-market motion2 records

Core offering

Biosyn Corporation manufactures clinical/GMP and research grade Keyhole Limpet Hemocyanin (KLH) and Immunocyanin products derived from the hemolymph of Megathura crenulata (Giant Keyhole Limpet), marketed under the trade names IMMUCOTHEL®, VACMUNE®, Native KLH, and Reassociated KLH (RANKLH). The company also manufactures Selenase® (sodium selenite pentahydrate), a selenium drug product indicated for selenium deficiency and investigated in sepsis, intensive care, and other clinical settings. Products are sold as bulk and vialed clinical/research materials for immunotherapy, antibody production, vaccine adjuvant, and pharmaceutical use.

Differentiator

Problem solved

Functional benefit

Brands

• IMMUCOTHEL®: biosyn's proprietary Immunocyanin (KLH subunit) lyophilized formulation developed for bladder cancer treatment; marketed in the Netherlands, Austria, Argentina and South Korea.
• VACMUNE®
• Native KLH
• Reassociated KLH (RANKLH)
• Selenase®

Products and services

• IMMUCOTHEL® Biosyn's proprietary lyophilized Immunocyanin (Keyhole Limpet Immunocyanin / KLI, ~400 kDa subunit) formulation developed for bladder cancer immunotherapy. It was the first hemocyanin product approved for the treatment of bladder cancer and is currently marketed in the Netherlands, Austria, Argentina and South Korea.
• VACMUNE® Biosyn's Immunocyanin (KLH subunits) offered as a carrier protein for vaccine manufacture, antibody production, and other immunological research applications. Available in liquid (IEX GMP Grade and Research Grade) and powder (Research Grade) forms, packaged as bulk and 1 mg, 10 mg, and 20 mg vials.
• Biosyn Native KLH Native Keyhole Limpet Hemocyanin derived from the hemolymph of Megathura crenulata (Giant Keyhole Limpet). Sold in multiple grades — GMP Grade, Research Grade, High Purity / Low Endotoxin Research Grade, and Low Endotoxin Research Grade — for use in immunotherapy, antibody production, immunology research, vaccine adjuvant, neoantigen, and immune status evaluation applications.
• Reassociated Native KLH (RANKLH) — High Molecular Weight Research Grade A biosyn product consisting of KLH subunits reassociated after an intermediate virus filtration step, formulated in phosphate buffered saline at ~10 mg/mL. Designed to overcome the limitations of virus filtration on native KLH and to serve as a well-defined alternative KLH formulation for conjugate vaccine manufacturers; GMP Grade available on request.
• Selenase® (sodium selenite pentahydrate) Biosyn's selenium product (sodium selenite pentahydrate), oral and injectable, registered as a drug product in more than 18 countries across Europe, Russia, Asia, and South America and indicated for selenium deficiency. In the U.S., it is marketed as an investigational product only, supported by an FDA Drug Master File; used in investigations for intensive care, sepsis, cardiosurgery, resuscitation, plastic surgery, organ transplantation and vascular surgery. Available in 1,000 µg dose vials for high-dose clinical usage.

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves7 records

Expansion highlights4 records

Emerging players

• bioMérieux: Microbiology and immunoassay company with adjuvants and carrier protein adjacencies. Comparable in the sense of building GMP immuno-diagnostic and immunotherapy reagent portfolios that touch KLH-adjacent value chains (vaccines, immunology research).

Broad incumbents

• Lonza Group: Global contract development and manufacturing organization with biologics and cell-and-gene therapy capabilities. Comparable as a GMP biomanufacturing peer that pharma customers use for similar upstream and downstream processing of immunotherapy and vaccine products.
• Thermo Fisher Scientific: Global life-sciences tools company that distributes Keyhole Limpet Hemocyanin as part of its research reagents catalog. Overlaps with biosyn's Native KLH and VACMUNE® research-grade offerings but operates across a vastly broader portfolio and is not specialized in GMP-grade hemocyanin.
• MilliporeSigma (Merck KGaA Life Science): Supplies KLH (including Imject mcKLH) as a research reagent and carrier protein under the legacy Sigma-Aldrich brand. Directly comparable to biosyn's Native KLH and VACMUNE® research-grade products, but as part of a much broader life-sciences catalog rather than a GMP-focused manufacturer.
• Fresenius Kabi: Major specialty/sterile injectable pharmaceutical manufacturer with a broad trace element and clinical nutrition portfolio that overlaps with biosyn's Selenase® injectable selenium franchise. Comparable in product format and hospital channel, though Fresenius operates at much larger scale.

Others

• Cytiva (Danaher): Supplies purification, filtration, and bioprocessing technologies that biosyn uses in KLH manufacturing. An ecosystem/equipment peer rather than a direct competitor, but relevant for understanding biosyn's manufacturing cost structure and GMP supply chain.

Regional players

• Helixor Heilmittel: German-rooted biopharmaceutical company developing mistletoe-based and other complementary oncology therapies. Comparable to biosyn's German subsidiary in jurisdiction and to IMMUCOTHEL®'s bladder cancer immunotherapy positioning in the European oncology market.
• Aguettant: European specialty injectable pharmaceutical manufacturer with trace element and electrolyte products. Directly comparable to Selenase® in product category, route of administration, and European hospital market positioning.

Direct peers

• Bio-Techne: Supplies proteins and reagents (including antibodies and immunology research tools) used in immunotherapy and vaccine research workflows that consume KLH. Closely comparable customer base (academic and pharma immunology labs) to biosyn's research-grade KLH buyers.
• Stellar Biotechnologies: Historically a direct competitor focused on sustainable KLH production from Megathura crenulata for immunotherapy and conjugate vaccine applications. Most directly comparable to biosyn in species, product format, and target market, though its current operating status is limited.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosyn